ATE342274T1 - Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon - Google Patents

Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon

Info

Publication number
ATE342274T1
ATE342274T1 AT04760861T AT04760861T ATE342274T1 AT E342274 T1 ATE342274 T1 AT E342274T1 AT 04760861 T AT04760861 T AT 04760861T AT 04760861 T AT04760861 T AT 04760861T AT E342274 T1 ATE342274 T1 AT E342274T1
Authority
AT
Austria
Prior art keywords
peptides
bind
apo2l
trail
receptors
Prior art date
Application number
AT04760861T
Other languages
English (en)
Inventor
Bing Li
Sachdev S Sidhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE342274T1 publication Critical patent/ATE342274T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04760861T 2003-05-09 2004-04-29 Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon ATE342274T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46943603P 2003-05-09 2003-05-09

Publications (1)

Publication Number Publication Date
ATE342274T1 true ATE342274T1 (de) 2006-11-15

Family

ID=33452286

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06013626T ATE423786T1 (de) 2003-05-09 2004-04-29 Peptide welche an apo2l (trail) rezeptoren binden und verwendungen davon
AT04760861T ATE342274T1 (de) 2003-05-09 2004-04-29 Peptide welche an apo2l (trail) rezeptoren binden und verwendungnen davon

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06013626T ATE423786T1 (de) 2003-05-09 2004-04-29 Peptide welche an apo2l (trail) rezeptoren binden und verwendungen davon

Country Status (12)

Country Link
US (1) US20070066800A1 (de)
EP (2) EP1622929B1 (de)
JP (1) JP2007530008A (de)
AT (2) ATE423786T1 (de)
AU (1) AU2004238794A1 (de)
CA (1) CA2524456A1 (de)
DE (2) DE602004002773T2 (de)
DK (2) DK1622929T3 (de)
ES (2) ES2322182T3 (de)
IL (1) IL171733A (de)
PL (2) PL1622929T3 (de)
WO (1) WO2004101608A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN102066403B (zh) * 2009-04-03 2014-10-08 中国医学科学院基础医学研究所 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途
CN102686606A (zh) * 2009-10-09 2012-09-19 阿纳福公司 结合il-23r的多肽
WO2015138638A1 (en) 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
DK3389696T3 (da) 2015-12-17 2024-12-16 Univ Johns Hopkins Ameliorating systemic sclerosis with death receptor agonists
KR102508650B1 (ko) 2016-04-07 2023-03-13 더 존스 홉킨스 유니버시티 사멸 수용체 작용제로써 췌장암 및 통증을 치료하기 위한 조성물 및 방법
CN116585484B (zh) * 2022-12-13 2023-12-12 广州医科大学 多肽偶联小分子化合物及其抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
IL171733A (en) 2010-11-30
DE602004019701D1 (de) 2009-04-09
US20070066800A1 (en) 2007-03-22
JP2007530008A (ja) 2007-11-01
ATE423786T1 (de) 2009-03-15
CA2524456A1 (en) 2004-11-25
DK1622929T3 (da) 2007-02-19
EP1622929A2 (de) 2006-02-08
WO2004101608A2 (en) 2004-11-25
EP1754713A1 (de) 2007-02-21
DE602004002773D1 (de) 2006-11-23
ES2322182T3 (es) 2009-06-17
DK1754713T3 (da) 2009-06-08
WO2004101608A3 (en) 2004-12-29
ES2274480T3 (es) 2007-05-16
AU2004238794A1 (en) 2004-11-25
DE602004002773T2 (de) 2007-08-16
EP1622929B1 (de) 2006-10-11
PL1754713T3 (pl) 2009-07-31
PL1622929T3 (pl) 2007-03-30
EP1754713B1 (de) 2009-02-25

Similar Documents

Publication Publication Date Title
DE60234202D1 (de) Taci-immunoglobulin-fusionsproteine
ATE423786T1 (de) Peptide welche an apo2l (trail) rezeptoren binden und verwendungen davon
PL1767546T3 (pl) Hamujące angiogenezę białka chimeryczne i ich zastosowanie
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
ATE517120T1 (de) Igf-1 fusion polypeptide und deren therapeutische verwendung
EP2031063A3 (de) Modulatoren von Duftrezeptoren
CO6180433A2 (es) Moleculas de enlace de lingo y uso farmaceutico de las mismas
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DE602005012555D1 (de) Künstliches protein zur absoluten quantifizierung von proteinen und verwendungen davon
PL378566A1 (pl) Ligandy dla białek wiążących TGF-beta i ich zastosowania
ATE373645T1 (de) Phenyltetrazol-verbindungen
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
DE60228504D1 (de) P53 bindende t-zellrezeptormoleküle und deren verwendungen
EP1978994A4 (de) Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen
EA200800205A1 (ru) Кальций-пептидный компонент
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
SE0202725D0 (sv) Anordning för magnetiskt inducerbar membrantransport
ATE483030T1 (de) Neue polynukleotid- und polypeptidsequenzen und deren verwendungen
MX2010003892A (es) Polipeptidos modificados de la hormona del crecimiento.
FI20040813A0 (fi) Hydrofobisia molekyylejä stabiloivat proteiinit

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1622929

Country of ref document: EP